1165P Modelling long-term survival outcomes in patients with stage (stg) IB–IIIA EGFR-mutated NSCLC from the ADAURA trial
Parneet Cheema, B. Heeg, M Dyer, Yi‐Long Wu, Thomas John, Frances A. Shepherd, Filippo de Marinis, Barbara Melosky, Benoît Samson, Daniel Moldaver, Sandra Shaw, Margarida S. Miranda, A. Verhoek
Topics & Concepts
MedicineOsimertinibInternal medicineOncologyHazard ratioReimbursementOverall survivalPlaceboStage (stratigraphy)CancerConfidence intervalAdenocarcinomaPathologyEconomicsHealth carePaleontologyAlternative medicineEconomic growthROS1BiologyLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesGastric Cancer Management and Outcomes